Krishnan Krish S sold $823K of KRYS
Krishnan Krish S (President and CEO) sold 2,652 shares of Krystal Biotech, Inc. (KRYS) at $310.43 ($0.82M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO/President executed an open-market sale of 2,652 shares at ~$310.43 on 2026-06-04; the disclosure was filed on 2026-06-05. The presence of a pre-arranged 10b5-1 plan reduces the likelihood that the sale signals new information.
Market read
A single insider sale can move short-term sentiment, but 10b5-1 typically limits fundamental interpretation.
What to watch
The filing does not disclose reasons for sale; traders should compare with prior insider activity cadence and whether any concurrent fundamental updates exist.
Background
This is an SEC Form 4 insider transaction disclosure for Krystal Biotech, Inc. (KRYS).
Ticker impact
Krystal Biotech CEO/President Krishnan Krish S sold $823K of KRYS shares via an open-market transaction filed on SEC Form 4.
Low-to-moderate short-term downside bias; likely limited follow-through given 10b5-1 pre-arrangement.
The filing is a concrete datapoint (sale size, price, date) but 10b5-1 reduces interpretability as a new negative signal.
Market effects
Limited read-across to biotech sector; this is company-specific insider activity without new clinical/regulatory catalysts.
None material beyond KRYS-specific sentiment.
None.
Counterpoint
Because the sale was under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the insider transaction disclosure (KRYS).
- insiderKrishnan Krish S
President and CEO; sold $823,257.71 of KRYS shares under a 10b5-1 plan.
